SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers
-
A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fibroblast Activation Protein Inhibitors (FAPI) radiopharmaceutical diagnostics - [68Ga]FAPI-46 and outside-
U.S. rights for [18F]FAPI-74 - FAP is highly expressed in cancer associated fibroblasts (CAF), which supports the growth and spread of cancerous cells across many tumor types1
-
SOFIE will maintain clinical development and commercialization rights for [18F]FAPI-74 in the
U.S. building on momentum from its FAPI Global Outreach Program
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231009674148/en/
Illustrative example: cancer associated fibroblasts (CAFs) and the tumor microenvironment. (Photo: Business Wire)
FAP is an enzyme highly expressed in cancer associated fibroblasts (CAF), a key component of the tumor microenvironment which supports the growth and spread of cancerous cells. With CAF present in most tumor types including, for example, breast, pancreatic, colorectal, lung, liver and gastric, the development of FAP-targeted diagnostics holds great potential in oncology as well as other conditions including inflammation, fibrosis and arthritis4.
Building on the momentum created by SOFIE’s sponsored trials in the
Usankar Thiru, Strategy & Evaluation Director with GE HealthCare’s
GE HealthCare’s
About
Follow us on Facebook, LinkedIn, Twitter, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
About
SOFIE’s vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services and high value theranostic intellectual property, SOFIE is poised to deliver on the promise of radiopharmaceuticals. For more information visit our website, https://sofie.com/ or contact us by email at info@sofie.com.
_______________________________
1 Xing, F., Saidou, J. and Watabe, K. (2010) Cancer associated fibroblasts (cafs) in tumor microenvironment, Frontiers in bioscience (Landmark edition). Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905156/ (Accessed:
2 Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma (FAPI-46 PDAC) - Full Text View - ClinicalTrials.gov. (n.d.). https://classic.clinicaltrials.gov/ct2/show/NCT05262855 (Accessed:
3 Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers - Full Text View - ClinicalTrials.gov. (n.d.). https://classic.clinicaltrials.gov/ct2/show/NCT05641896 (Accessed:
4 Dendl, K., Koerber, S. A., Kratochwil, C., Cardinale, J., Finck, R., Dabir, M., Novruzov, E., Watabe, T., Kramer, V., Choyke, P. L., Haberkorn, U., & Giesel, F. L. (2021). FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? Cancers, 13(19), 4946. https://doi.org/10.3390/cancers13194946. Available at: https://www.mdpi.com/2072-6694/13/19/4946 (Accessed:
View source version on businesswire.com: https://www.businesswire.com/news/home/20231009674148/en/
GE HealthCare Media Contact:
Mathilde Bouscaillou
M 033 647 008 271
Mathilde.Bouscaillou@ge.com
Marketing Manager
dawn.allen@sofie.com
Source: